Skip to content
2000
Volume 13, Issue 1
  • ISSN: 2211-5560
  • E-ISSN: 2211-5579

Abstract

Donanemab is the first antibody to target pyroglutamate-modified amyloid-beta in Alzheimer's disease selectively; thus, it represents a significant breakthrough in disease-modifying treatments. Importantly, its mechanism of action encourages adequate clearance of plaques and does not even worsen outcomes for early-stage patients, in contrast to previous treatments that did not promote clearing for plaques or even worsened the outcomes of early-stage patients. The integration of quantum computing in drug discovery holds tremendous transformations in terms of enhancing the therapeutic approach against Alzheimer's disease. Researchers can speed up discovering novel compounds, optimize treatment regimens, and personalize patient care according to individual neurobiological profiles by using quantum computing powers. The letter to the editor discusses the unique attributes of donanemab, its clinical superiority, and the related side effects, besides pushing for the promising future of integrating quantum computing into the paradigms of Alzheimer's treatment. Though promising, integrating quantum computing into medical practice is challenged by factors such as high computational costs, data privacy, and ethical considerations that must be taken within strict regulatory frameworks.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpsp/10.2174/0122115560361749250110074639
2025-01-01
2025-09-10

  • From This Site

    /content/journals/cpsp/10.2174/0122115560361749250110074639
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. UchidaY. KanH. SakuraiK. OishiK. MatsukawaN. Contributions of blood–brain barrier imaging to neurovascular unit pathophysiology of Alzheimer’s disease and related dementias.Front. Aging Neurosci.202315111144810.3389/fnagi.2023.111144836861122
     [Google Scholar]
  2. UchidaY. KanH. FurukawaG. OndaK. SakuraiK. TakadaK. MatsukawaN. OishiK. Relationship between brain iron dynamics and blood-brain barrier function during childhood: A quantitative magnetic resonance imaging study.Fluids Barriers CNS20232016010.1186/s12987‑023‑00464‑x37592310
     [Google Scholar]
  3. ZhaoZ. LiuY. RuanS. HuY. Current anti-amyloid-β therapy for Alzheimer’s disease treatment: From clinical research to nanomedicine.Int. J. Nanomedicine2023187825784510.2147/IJN.S44411538144511
     [Google Scholar]
  4. SimsJ.R. ZimmerJ.A. EvansC.D. LuM. ArdayfioP. SparksJ. WesselsA.M. ShcherbininS. WangH. Monkul NeryE.S. CollinsE.C. SolomonP. SallowayS. ApostolovaL.G. HanssonO. RitchieC. BrooksD.A. MintunM. SkovronskyD.M. AbreuR. AgarwalP. AggarwalP. AgroninM. AllenA. AltamiranoD. AlvaG. AndersenJ. AndersonA. AndersonD. ArnoldJ. AsadaT. AsoY. AtitV. AyalaR. BadruddojaM. Badzio-jagielloH. BajacekM. BartonD. BearD. BenjaminS. BergeronR. BhatiaP. BlackS. BlockA. BolouriM. BondW. BouthillierJ. BrangmanS. BrewB. BrisbinS. BriskenT. BrodtmannA. BrodyM. BroschJ. BrownC. BrownstoneP. BukowczanS. BurnsJ. CabreraA. CapoteH. CarrascoA. Cevallos YepezJ. ChavezE. ChertkowH. Chyrchel-paszkiewiczU. CiabarraA. ClemmonsE. CohenD. CohenR. CohenI. ConchaM. CostellB. CrimminsD. Cruz-paganY. CueliA. CupeloR. CzarneckiM. DarbyD. DautzenbergP. De DeynP. De La GandaraJ. DeckK. DibenedettoD. DibuonoM. DinnersteinE. DiricanA. DixitS. DobryniewskiJ. DrakeR. DrysdaleP. DuaraR. DuffyJ. EllenbogenA. FaradjiV. FeinbergM. FeldmanR. FishmanS. FlitmanS. ForchettiC. FragaI. FrankA. FrishbergB. FujigasakiH. FukaseH. FumeroI. FurihataK. GallowayC. GandhiR. GeorgeK. GermainM. GitelmanD. GoetschN. GoldfarbD. GoldsteinM. GoldstickL. Gonzalez RojasY. GoodmanI. GreeleyD. GriffinC. GrigsbyE. GroszD. HafnerK. HartD. HeneinS. HerskowitzB. HigashiS. HigashiY. HoG. HodgsonJ. HohenbergM. HollenbeckL. HolubR. HoriT. HortJ. IlkowskiJ. IngramK.J. IsaacM. IshikawaM. JanuL. JohnstonM. JulioW. JustizW. KagaT. KakigiT. KalaferM. KamijoM. KaplanJ. KarathanosM. KatayamaS. KaulS. KeeganA. KerwinD. KhanU. KhanA. KimuraN. KirkG. KlodowskaG. KowaH. KutzC. KwentusJ. LaiR. LallA. LawrenceM. LeeE. LeonR. LinkerG. LisewskiP. LissJ. LiuC. LoskS. LukaszykE. LynchJ. MacfarlaneS. MacsweeneyJ. ManneringN. MarkovicO. MarksD. MasdeuJ. MatsuiY. MatsuishiK. McallisterP. McconneheyB. McelveenA. McgillL. MeccaA. MegaM. MensahJ. MickielewiczA. MinaeianA. MocherlaB. MurphyC. MurphyP. NagashimaH. NairA. NairM. NardandreaJ. NashM. NasreddineZ. NishidaY. NortonJ. NunezL. OchiaiJ. OhkuboT. OkamuraY. OkorieE. OliveraE. O’mahonyJ. OmidvarO. Ortiz-CruzD. OsowaA. PapkaM. ParkerA. PatelP. PatelA. PatelM. PatryC. PeckhamE. PfefferM. PietrasA. PlopperM. PorsteinssonA. Poulin RobitailleR. PrinsN. PuenteO. RatajczakM. RheeM. RitterA. RodriguezR. Rodriguez AblesL. RojasJ. RossJ. RoyerP. RubinJ. RussellD. RutgersS.M. RutrickS. SadowskiM. SafirsteinB. SagisakaT. ScharreD. SchneiderL. SchreiberC. SchriftM. SchulzP. SchwartzH. SchwartzbardJ. ScottJ. SelemL. SethiP. ShaS. SharlinK. SharmaS. ShiovitzT. ShiwachR. SladekM. SloanB. SmithA. SolomonP. SorialE. SosaE. StedmanM. SteenS. SteinL. StolyarA. StoukidesJ. SudohS. SuttonJ. SyedJ. SzigetiK. TachibanaH. TakahashiY. TatenoA. TaylorJ.D. TaylorK. TcheremissineO. ThebaudA. TheinS. ThurmanL. ToenjesS. TojiH. TomaM. TranD. TruebaP. TsujimotoM. TurnerR. UchiyamaA. UssorowskaD. VaishnaviS. ValorE. VandersluisJ. VasquezA. VelezJ. VergheseC. Vodickova-borzovaK. WatsonD. WeidmanD. WeismanD. WhiteA. WillinghamK. WinkelI. WinnerP. WinstonJ. WolffA. YagiH. YamamotoH. YathirajS. YoshiyamaY. ZbochM. TRAILBLAZER-ALZ 2 Investigators Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.JAMA2023330651252710.1001/jama.2023.1323937459141
     [Google Scholar]
  5. DecourtB. NoordaK. NoordaK. ShiJ. SabbaghM.N. Review of advanced drug trials focusing on the reduction of brain beta-amyloid to prevent and treat dementia.J. Exp. Pharmacol.20221433135210.2147/JEP.S26562636339394
     [Google Scholar]
  6. JeongS.Y. SuhC.H. KimS.J. LemereC.A. LimJ.S. LeeJ.H. Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for alzheimer’s disease: Recent updates on clinical and imaging features and MRI monitoring.Korean J. Radiol.202425872674110.3348/kjr.2024.010539109501
     [Google Scholar]
  7. DoranS.J. SawyerR.P. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications.Front. Neurosci.202418132678410.3389/fnins.2024.132678438312931
     [Google Scholar]
  8. VukmirR.B. Amyloid‐related imaging abnormalities (ARIA): Diagnosis, management, and care in the setting of amyloid‐modifying therapy.Ann. Clin. Transl. Neurol.20241171669168010.1002/acn3.5204238939962
     [Google Scholar]
  9. LiuE. ZhangY. WangJ.Z. Updates in Alzheimer’s disease: From basic research to diagnosis and therapies.Transl. Neurodegener.20241314510.1186/s40035‑024‑00432‑x39232848
     [Google Scholar]
  10. PatilB. LadM. SharmaP. SantaniN. RajpalM. ShaikhS. Revolutionizing Alzheimer’s diagnosisusing quantum computing.2024 International Conference on Inventive Computation Technologies (ICICT)Apr 24, 2024, pp. 479-85.10.1109/ICICT60155.2024.10544797
     [Google Scholar]
  11. LiW. YinZ. LiX. MaD. YiS. ZhangZ. ZouC. BuK. DaiM. YueJ. ChenY. ZhangX. ZhangS. A hybrid quantum computing pipeline for real world drug discovery.Sci. Rep.20241411694210.1038/s41598‑024‑67897‑839043787
     [Google Scholar]
  12. FrançaV.L.B. BezerraE.M. da CostaR.F. CarvalhoH.F. FreireV.N. MatosG. Alzheimer’s disease immunotherapy and mimetic peptide design for drug development: Mutation screening, molecular dynamics, and a quantum biochemistry approach focusing on aducanumab: Aβ2–7 binding affinity.ACS Chem. Neurosci.202415193543356210.1021/acschemneuro.4c0045339302203
     [Google Scholar]
  13. DeyA. GhoshS. RajendranR.L. BhuniyaT. DasP. BhattacharjeeB. DasS. MahajanA.A. SamantA. KrishnanA. AhnB.C. GangadaranP. Alzheimer’s disease pathology and assistive nanotheranostic approaches for its therapeutic interventions.Int. J. Mol. Sci.20242517969010.3390/ijms2517969039273645
     [Google Scholar]
/content/journals/cpsp/10.2174/0122115560361749250110074639
Loading

  • Article Type:     Editorial
Keyword(s): Alzheimer’s disease; amyloid plaques; donanemab; machine learning; patient care; quantum computing

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test